Casdatifan + Zimberelimab for Kidney Cancer

This trial tests whether the drug casdatifan is safe and effective for treating kidney cancer, either alone or combined with zimberelimab (an immunotherapy drug). It focuses on clear cell renal cell carcinoma, a type of kidney cancer. Participants will be divided into two groups: one receiving only casdatifan and another receiving both casdatifan and zimberelimab. This trial may suit individuals with kidney cancer that can be surgically removed and who meet specific health criteria.

As a Phase 2 trial, the research measures how well the treatment works in an initial, smaller group of people.

The trial requires a washout period (time without taking certain medications) of 28 days for those taking strong CYP3A4 inhibitors and inducers before starting casdatifan. If you are on these medications, you will need to stop them before joining the trial.

A previous study found that casdatifan was well tolerated by patients with kidney cancer, meaning most did not stop using it due to side effects. Another study also showed that very few people discontinued casdatifan, indicating good safety.

When combined with zimberelimab, research shows that this combination has a manageable safety profile, meaning side effects can be handled without stopping treatment.

Researchers are excited about Casdatifan and Zimberelimab for kidney cancer because they bring new approaches to treatment. Unlike standard treatments like surgery, radiation, or chemotherapy, Casdatifan and Zimberelimab target cancer cells more precisely. Casdatifan is a new active ingredient that works through a novel mechanism, possibly offering a more targeted attack on cancer cells. Zimberelimab, an immune checkpoint inhibitor, helps the immune system recognize and fight cancer cells, potentially boosting the body's natural defenses. This combination could offer more effective and less invasive options than current standard treatments.

Research shows that casdatifan, a drug that blocks a protein involved in cancer growth, holds promise for treating clear cell renal cell carcinoma (ccRCC). Studies have found that 25% to 33% of patients taking casdatifan experience their cancer shrinking or halting its growth. Additionally, casdatifan has been linked to longer periods where the cancer does not worsen. In this trial, participants in Group A will receive casdatifan alone.